Eli Lilly and Co LLY

Morningstar Rating
$1,347.11 −4.01 (0.30%)
View Full Chart

Company Report

Price vs Fair Value

LLY is trading at a LOCK|!x&>!bK premium.
Price
$1,347.11
Fair Value
LOCK|ND
Uncertainty
LOCK|>^
1-Star Price
LOCK|^jQ
5-Star Price
F!g
Economic Moat
LOCK|@nV
Capital Allocation
LOCK|$RDGL&!

Bulls Say, Bears Say

Bulls

Lilly's strong leadership in weight-loss drugs should drive industry-leading growth, given its approved drugs and well-positioned next-generation weight-loss drugs in the pipeline.

Bears

The risks to success for Kisunla remain high because of bottlenecks in patient diagnosis, required scans and monitoring, and competition, particularly from Eisai/Biogen (Leqembi) and Roche (pipeline drug trontinemab).

News

Articles & Videos

Trading Information

Previous Close Price
$1,351.12
Day Range
$1,341.76–1,372.05
52-Week Range
$850.51–1,475.25
Bid/Ask
$1,345.50 / $1,348.50
Shares Outstanding
890.75M
Market Cap
$1.20T
Volume/Avg
4M / 3M

Key Statistics

Price/Earnings (Normalized)
42.16
Price/Sales
13.95
Dividend Yield (Trailing)
0.51%
Dividend Yield (Forward)
0.51%
Dividend Payment Schedule
Mar, Jun, Sep, Dec
Total Yield
1.00%

Company Profile

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Growth
Total Number of Employees
50,000

Competitors

Valuation

Metric
LLY
NVO
MRK
Price/Earnings (Normalized)
42.169.3742.86
Price/Book Value
29.815.057.35
Price/Sales
13.953.244.91
Price/Cash Flow
33.308.5214.95
Price/Earnings
LLY
NVO
MRK

Financial Strength

Metric
LLY
NVO
MRK
Quick Ratio
0.640.630.78
Current Ratio
1.390.841.35
Interest Coverage
33.96—3.33
Quick Ratio
LLY
NVO
MRK

Profitability

Metric
LLY
NVO
MRK
Return on Assets (Normalized)
22.55%20.15%5.90%
Return on Equity (Normalized)
91.88%56.25%16.36%
Return on Invested Capital (Normalized)
37.89%33.34%9.36%
Return on Assets
LLY
NVO
MRK

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Johnson & Johnson
JNJ
LOCK|!L#C%sMLOCK|Rg$651B
AbbVie Inc
ABBV
LOCK|Dy$Sq!LOCK|&D%$506B
Roche Holding AG ADR
RHHBY
LOCK|ndH!@!<bLOCK|>q$375B
Merck & Co Inc
MRK
LOCK|pXG<>>LOCK|F>$330B
Novartis AG ADR
NVS
LOCK|>!hsw%$LOCK|^JC$286B
AstraZeneca PLC
AZN
LOCK|t%Gx>#l$LOCK|#G$272B
Amgen Inc
AMGN
LOCK|F#lL%?$LOCK|p&$236B
Gilead Sciences Inc
GILD
LOCK|V#l@K^LOCK|#f$206B
Novo Nordisk AS ADR
NVO
LOCK|v$#<&HLOCK|Np$171B

Sponsor Center